PriceTargets.com logo

Alkermes - ALKS Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $31.67
  • Forecasted Upside: 7.31%
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 3 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$29.51 As of 06/2/2023 06:34 PM ET
▲ +0.23 (0.79%)

This chart shows the closing price for ALKS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Alkermes Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ALKS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ALKS

Analyst Price Target is $31.67
▲ +7.31% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Alkermes in the last 3 months. The average price target is $31.67, with a high forecast of $37.00 and a low forecast of $28.00. The average price target represents a 7.31% upside from the last price of $29.51.

This chart shows the closing price for ALKS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 5 contributing investment analysts is to hold stock in Alkermes. This rating has held steady since January 2023, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 5 hold ratings
  • 0 sell ratings
Ratings as of
12/9/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 5 hold ratings
  • 0 sell ratings
Ratings as of
3/9/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 5 hold ratings
  • 0 sell ratings
Ratings as of
6/7/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
9/5/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
12/4/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 5 hold ratings
  • 0 sell ratings
Ratings as of
3/4/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
5/3/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
6/2/2023

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/27/2023HC WainwrightBoost Target$32.00 ➝ $34.00Low
4/25/2023JPMorgan Chase & Co.Boost Target$29.00 ➝ $31.00Low
4/11/2023MizuhoBoost TargetBuy$36.00 ➝ $37.00Low
2/17/2023HC WainwrightReiterated RatingNeutral$32.00Low
2/16/2023Stifel NicolausBoost Target$30.00Low
1/8/2023Bank of AmericaBoost Target$27.00 ➝ $28.00Low
12/6/2022JPMorgan Chase & Co.Lower TargetNeutral$33.00 ➝ $29.00Low
11/22/2022MizuhoBoost TargetBuy$34.00 ➝ $36.00Low
11/3/2022Piper SandlerUpgradeNeutral ➝ Overweight$26.00 ➝ $30.00Low
10/14/2022Bank of AmericaUpgradeUnderperform ➝ Neutral$27.00 ➝ $25.00Low
8/16/2022Piper SandlerInitiated CoverageNeutral$26.00Low
7/28/2022MizuhoLower TargetBuy$36.00 ➝ $34.00Low
7/27/2022Stifel NicolausBoost Target$28.00Low
4/28/2022MizuhoBoost Target$35.00 ➝ $36.00High
4/28/2022HC WainwrightBoost Target$30.00 ➝ $32.00High
4/27/2022Stifel NicolausBoost Target$24.00 ➝ $27.00High
4/21/2022SVB LeerinkBoost TargetMarket Perform$24.00 ➝ $25.00Low
4/20/2022The Goldman Sachs GroupInitiated CoverageBuy$35.00Medium
3/22/2022CitigroupBoost TargetNeutral$22.00 ➝ $26.00High
2/17/2022MizuhoBoost Target$33.00 ➝ $35.00High
1/27/2022Cantor FitzgeraldUpgradeHold ➝ Overweight$32.00High
12/1/2021CitigroupInitiated CoverageNeutral$22.00High
11/9/2021MizuhoLower TargetNeutral$36.00 ➝ $33.00High
11/9/2021SVB LeerinkLower TargetMarket Perform$27.00 ➝ $24.00High
10/28/2021HC WainwrightBoost TargetNeutral$25.00 ➝ $30.00Medium
10/27/2021Stifel NicolausBoost TargetHold$25.00 ➝ $29.00Medium
10/6/2021Jefferies Financial GroupUpgradeHold ➝ Buy$36.00High
9/10/2021MizuhoReiterated RatingBuy$33.00 ➝ $36.00Medium
9/2/2021Bank of AmericaDowngradeNeutral ➝ Underperform$25.00 ➝ $27.00Low
7/29/2021SVB LeerinkBoost TargetMarket Perform$23.00 ➝ $25.00Low
7/29/2021MizuhoBoost TargetBuy$29.00 ➝ $33.00Low
6/2/2021HC WainwrightBoost TargetNeutral$24.00 ➝ $25.00Low
6/1/2021MizuhoReiterated RatingBuy$29.00High
4/29/2021HC WainwrightBoost TargetNeutral$23.00 ➝ $24.00Low
4/26/2021MizuhoBoost TargetBuy$28.00 ➝ $29.00High
1/7/2021MizuhoBoost Target$24.00 ➝ $28.00N/A
12/11/2020SVB LeerinkBoost TargetMarket Perform$18.00 ➝ $23.00Medium
11/10/2020HC WainwrightReiterated RatingHoldLow
10/15/2020MizuhoUpgradeNeutral ➝ Buy$19.00 ➝ $24.00Low
10/7/2020JPMorgan Chase & Co.Reiterated RatingHoldMedium
9/30/2020Bank of AmericaLower TargetNeutral$21.00 ➝ $19.00Medium
9/21/2020JPMorgan Chase & Co.Reiterated RatingHoldLow
7/30/2020HC WainwrightReiterated RatingHold$23.00Medium
7/30/2020MizuhoBoost TargetNeutral$16.00 ➝ $19.00High
7/30/2020The Goldman Sachs GroupDowngradeNeutral ➝ Sell$19.00 ➝ $15.00High
4/30/2020HC WainwrightReiterated RatingNeutral$25.00 ➝ $23.00High
4/29/2020Piper SandlerLower TargetNeutral$22.00 ➝ $21.00High
4/29/2020Stifel NicolausLower TargetAverage ➝ Hold$20.00 ➝ $17.00High
4/29/2020MizuhoReiterated RatingHold$16.00High
4/2/2020Morgan StanleyLower TargetEqual Weight$20.00 ➝ $16.00Low
3/23/2020Bank of AmericaLower TargetNeutral$20.00 ➝ $17.00Medium
2/14/2020HC WainwrightLower TargetNeutral$26.00 ➝ $25.00High
2/14/2020Bank of AmericaDowngradeBuy ➝ Neutral$31.00 ➝ $20.00High
2/14/2020CowenReiterated RatingBuy$28.00High
2/13/2020JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$25.00 ➝ $21.00Low
2/13/2020Stifel NicolausLower TargetHold$23.00 ➝ $20.00Low
2/5/2020MizuhoInitiated CoverageNeutral$19.00Medium
1/31/2020Wolfe ResearchUpgradeUnderperform ➝ Peer Perform$21.00Low
1/24/2020SVB LeerinkReiterated RatingMarket PerformLow
1/24/2020CowenReiterated RatingBuyHigh
11/1/2019HC WainwrightLower TargetNeutral$28.00 ➝ $26.00Low
10/23/2019Stifel NicolausLower TargetHold$25.00 ➝ $23.00High
10/18/2019HC WainwrightReiterated RatingHold$28.00Low
9/13/2019CowenSet TargetBuy$34.00High
9/5/2019Morgan StanleyUpgradeUnderweight ➝ Equal$30.00 ➝ $20.00Medium
7/26/2019CitigroupSet TargetHold$25.00N/A
7/25/2019Piper Jaffray CompaniesLower TargetNeutral$30.00 ➝ $22.00Medium
7/15/2019The Goldman Sachs GroupUpgradeSell ➝ Neutral$27.00High
5/31/2019HC WainwrightInitiated CoverageNeutral ➝ Neutral$28.00 ➝ $28.00High
5/1/2019CitigroupDowngradeBuy ➝ Neutral$62.00 ➝ $33.00High
4/26/2019Credit Suisse GroupSet TargetSell$28.00Medium
4/10/2019JPMorgan Chase & Co.Reiterated RatingBuyHigh
2/15/2019Credit Suisse GroupUpgradeHold$30.00High
2/15/2019Stifel NicolausLower TargetHold$40.00 ➝ $34.00N/A
1/23/2019Cantor FitzgeraldSet TargetHold$33.00Low
1/10/2019JPMorgan Chase & Co.Reiterated RatingBuyLow
12/18/2018The Goldman Sachs GroupDowngradeNeutral ➝ Sell$49.00 ➝ $26.00High
12/14/2018Wolfe ResearchInitiated CoverageUnderperform ➝ UnderperformMedium
12/13/2018Credit Suisse GroupDowngradeOutperform ➝ Underperform$47.00 ➝ $31.00High
11/12/2018SVB LeerinkInitiated CoverageMarket Perform$36.00Medium
11/5/2018Cantor FitzgeraldReiterated RatingNeutral ➝ Neutral$46.00 ➝ $41.00High
11/5/2018Piper Jaffray CompaniesInitiated CoverageNeutral ➝ Neutral$40.00Low
11/2/2018Stifel NicolausLower TargetHold$44.00 ➝ $40.00High
10/30/2018CowenReiterated RatingBuy$58.00Medium
10/23/2018Cantor FitzgeraldReiterated RatingHold$46.00Low
8/6/2018Stifel NicolausInitiated CoverageHold$45.00Low
7/27/2018Credit Suisse GroupLower TargetOutperform ➝ Buy$57.00 ➝ $51.00High
7/27/2018Bank of AmericaLower TargetBuy ➝ Buy$56.00 ➝ $54.00High
7/8/2018JPMorgan Chase & Co.Reiterated RatingBuyMedium
7/2/2018JPMorgan Chase & Co.Reiterated RatingBuyMedium
6/28/2018Morgan StanleyDowngradeEqual Weight ➝ UnderweightLow
6/21/2018Morgan StanleyDowngradeEqual Weight ➝ Underweight$67.00 ➝ $42.00High
6/6/2018B. RileyInitiated CoverageBuy$60.00High
(Data available from 6/2/2018 forward)

News Sentiment Rating

0.86 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 7 very positive mentions
  • 12 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/4/2022
  • 2 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/4/2022
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
1/3/2023
  • 7 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/2/2023
  • 11 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/4/2023
  • 8 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
4/3/2023
  • 10 very positive mentions
  • 21 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/3/2023
  • 14 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/2/2023

Current Sentiment

  • 14 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Alkermes logo
Alkermes Plc is a global biopharmaceutical company, which engages in the business of developing, manufacturing, and commercializing medicines designed to address unmet medical needs of patients in major therapeutic areas such as alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurological disorders and cancer. Its proprietary products include ARISTADA, ARISTADA INITIO, LYBALVI, and VIVITROL. The company was founded in 1987 and is headquartered in Dublin, Ireland.
Read More

Today's Range

Now: $29.51
Low: $28.93
High: $29.57

50 Day Range

MA: $29.31
Low: $26.49
High: $31.37

52 Week Range

Now: $29.51
Low: $21.75
High: $32.23

Volume

991,581 shs

Average Volume

1,285,303 shs

Market Capitalization

$4.90 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.6

Frequently Asked Questions

What sell-side analysts currently cover shares of Alkermes?

The following sell-side analysts have issued stock ratings on Alkermes in the last year: Bank of America Co., HC Wainwright, JPMorgan Chase & Co., Mizuho, Piper Sandler, Stifel Nicolaus, and StockNews.com.
View the latest analyst ratings for ALKS.

What is the current price target for Alkermes?

6 Wall Street analysts have set twelve-month price targets for Alkermes in the last year. Their average twelve-month price target is $31.67, suggesting a possible upside of 7.3%. Mizuho has the highest price target set, predicting ALKS will reach $37.00 in the next twelve months. Bank of America Co. has the lowest price target set, forecasting a price of $28.00 for Alkermes in the next year.
View the latest price targets for ALKS.

What is the current consensus analyst rating for Alkermes?

Alkermes currently has 3 hold ratings and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in ALKS, but not buy more shares or sell existing shares.
View the latest ratings for ALKS.

What other companies compete with Alkermes?

Other companies that are similar to Alkermes include Madrigal Pharmaceuticals, Ionis Pharmaceuticals, Amicus Therapeutics, ImmunoGen and Ironwood Pharmaceuticals. Learn More about companies similar to Alkermes.

How do I contact Alkermes' investor relations team?

Alkermes' physical mailing address is 1 BURLINGTON ROAD CONNAUGHT HOUSE, DUBLIN L2, DUBLIN 4. The company's listed phone number is (531) 772-8000 and its investor relations email address is invest[email protected]. The official website for Alkermes is www.alkermes.com. Learn More about contacing Alkermes investor relations.